Alterations in renal function have been described with telaprevir (TVR). We examined the relationship between ribavirin (RBV) trough concentration (C), estimated glomerular filtration rate (eGFR) and severe anaemia, before and after TVR introduction in HIV–HCV-coinfected patients included in ANRS HC26 TelapreVIH study.
Methods
69 HIV–HCV genotype-1 coinfected patients received 4 weeks of pegylated interferon (PEG-IFN)-α2a/RBV, followed by 12 weeks of TVR/PEG-IFN/RBV, then 32 to 56 weeks of PEG-IFN/RBV. RBV C was determined at week (W)4, W8 and W20/24. eGFR was estimated by the Modification of the Diet in Renal Disease (MDRD) equation. Severe anaemia was defined as haemoglobin <70 g/l, RBV dose reduction, prescription of erythropoietin or blood transfusion.
Results
67 patients were analysed. eGFR remained normal between baseline (97.9 ml/min) and W4 (103.4 ml/min), declined to 86.3 ml/min at W8 (P<0.0001), stabilized until W16 and increased back to baseline level at W20 (98.4 ml/min). RBV C increased from 1.88 mg/l at W4 to 2.88 mg/l at W8 (P<0.0001), then decreased to 2.73 mg/l at week 20/24 (P=0.015). An inverse correlation was observed between W8 eGFR and W8 RBV C (r2=0.429; P=0.0005). RBV C≥3 mg/l was observed in 12% of patients at W4, 45% at W8 (P<0.0001) and 38% at W20/24 (P=0.0005). Severe anaemia was observed in 23.9% of patients at W4 and 45.3% at W8. RBV C≥3 mg/l at W8 (OR 7.7 [95% CI 2.2, 27.4]) and baseline haemoglobin <150 g/l (OR 6.4 [1.7, 23.8]) were independently associated with W8 severe anaemia.
Conclusions
Association of TVR to PEG-IFN/RBV was associated with a decrease in eGFR and increase in RBV C, leading to severe anaemia in 45% of patients.
ZeuzemS., AndreoneP., PolS.Telaprevir for retreatment of HCV infection.N Engl J Med2011; 364: 2417–2428.
5.
SitoleM., SilvaM., SpoonerL., ComeeM.K., MalloyM.Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from Phase II and III trials.Clin Ther2013; 35: 190–197.
6.
BorroniG., CazzanigaM., AndreolettiM.Low glomerular filtration rate is a risk factor for ribavirin-associated anaemia in old patients with chronic hepatitis C.J Viral Hepat2013; 20: e90–e95.
7.
GlueP.The clinical pharmacology of ribavirin.Semin Liver Dis1999; 19Suppl 1: 17–24.
8.
GuptaS.K., KantesariaB., GlueP.Pharmacokinetics, safety, and tolerability of ribavirin in hemodialysis-dependent patients.Eur J Clin Pharmacol2012; 68: 415–418.
9.
GuptaS.K., KantesariaB., GlueP.Exploring the influence of renal dysfunction on the pharmaco-kinetics of ribavirin after oral and intravenous dosing.Drug Discov Ther2014; 8: 89–95.
RendónA.L., NunezM., RomeroM.Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients.J Acquir Immune Defic Syndr2005; 39: 401–405.
13.
BrochotE., CastelainS., DuverlieG., CapronD., Nguyen-KhacE., FrancoisC.Ribavirin monitoring in chronic hepatitis C therapy: anaemia versus efficacy.Antivir Ther2010; 15: 687–695.
14.
ChevaliezS., HezodeC., SoulierA.High-dose pegylated interferon-alpha and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype (SYREN trial).Gastroenterology2011; 141: 119–127.
15.
LeveyA.S., BoschJ.P., LewisJ.B., GreeneT., RogersN., RothD.A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.Ann Intern Med1999; 130: 461–470.
16.
LeveyA.S., EckardtK.U., TsukamotoY.Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).Kidney Int2005; 67: 2089–2100.
17.
KarinoT., OzekiI., HigeS.Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C.J Viral Hepat2014; 21: 341–347.
18.
KarinoY., HigeS., NakajimaT.Telaprevir induced renal dysfunction leads to an early elevation of serum ribavirin concentration in triple therapy.Hepatology2012; 56Suppl 1: 1005A–1006A.
19.
TempestilliM., D'OffiziG., LionettiR.Increased plasma concentration of ribavirin as a result of renal dysfunction in HCV patients treated with telaprevir.Hepatology2014; 60: 1109–1110.
20.
MaussS., HueppeD., AlshuthU.Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir.Hepatology2014; 59: 46–48.
21.
FukudaK., ImaiY., HiramatsuN.Renal impairment during the treatment of telaprevir with peginterferon and ribavirin in patients with chronic hepatitis C.Hepatol Res2014; 44: 1165–1171.
22.
KunzeA., HuwylerJ., CamenischG., GutmannH.Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters.Biochem Pharmacol2012; 84: 1096–1102.
23.
Meyer zu SchwabedissenH.E., VerstuyftC., KroemerH.K., BecquemontL., KimR.B.Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms.Am J Physiol Renal Physiol2010; 298: F997–F1005.
24.
NakadaT., KitoT., InoueK.Evaluation of the potency of telaprevir and its metabolites as inhibitors of renal organic cation transporters, a potential mechanism for the elevation of serum creatinine.Drug Metab Pharmacokinet2014; 29: 266–271.
25.
GervasoniC., MilazzoL., PezzaniD., FucileS., CattaneoD.Telaprevir therapy, renal impairment, and their effects on the pharmacokinetics of tenofovir in HIV/hepatitis C virus coinfected patients.AIDS2014; 28: 285–287.
26.
HallA.M.Update on tenofovir toxicity in the kidney.Pediatr Nephrol2013; 28: 1011–1023.
27.
RyomL., MocroftA., LundgrenJ.HIV therapies and the kidney: some good, some not so good?Curr HIV/AIDS Rep2012; 9: 111–120.
28.
SievertW., DoreG.J., McCaughanG.W.Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1.Hepatology2011; 53: 1109–1117.
29.
SulkowskiM.S., ShiffmanM.L., AfdhalN.H.Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate.Gastroenterol2010; 139: 1602–1611.
30.
MaynardM., GagnieuM.C., PradatP., SouvignetC., TrepoC.Prediction of sustained virological response by ribavirin plasma concentration at week 4 during pegylated-interferon/ribavirin combination therapy in HCV patients.J Hepatol2007; 46: S234.
31.
van VlerkenL.G., van OijenM.G., van ErpecumK.J.Ribavirin concentration is a more important predictor of sustained viral response than anemia in hepatitis C patients.Gastroenterol2011; 140: 1693–1694.
32.
GargV., KauffmanR.S., BeaumontM., van HeeswijkR.P.Telaprevir: pharmacokinetics and drug interactions.Antivir Ther2012; 17: 1211–1221.
33.
AghemoA., GrassiE., RumiM.G.Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving telaprevir.PLoS ONE2014; 9: e95881.
HoofnagleJ.H., SherkerA.H.Therapy for hepatitis C–the costs of success.N Engl J Med2014; 370: 1552–1553.
36.
BrennanB.J., WangK., BlotnerS.Safety, tolerability, and pharmacokinetics of ribavirin in hepatitis C virus-infected patients with various degrees of renal impairment.Antimicrob Agents Chemother2013; 57: 6097–6105.
37.
HuC.C., WengC.H., LinC.L.Predictors of changes in hemoglobin levels in patients with chronic hepatitis C treated with ribavirin plus pegylated interferon-alpha.Ren Fail2012; 34: 429–434.
38.
AkamatsuS., HayesC.N., TsugeM.Ribavirin dose reduction during telaprevir/ribavirin/peg-interferon therapy overcomes the effect of the ITPA gene polymorphism.J Viral Hepat2015; 22: 166–174.
39.
RobertsS.K., AndreoneP., PolS.Impact of anemia and ribavirin dose reduction on SVR in a telaprevir-based regimen in patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure in the Phase III REALIZE study.Hepatology2011; 54: 1007A–1008A.
40.
SulkowskiM.S., ReddyR., AfdhalN.H.Anemia had no effect on efficacy outcomes in treatment-naive patients who received telaprevir-based regimen in the ADVANCE and ILLUMINATE Phase 3 Studies.J Hepatol2011; 54: S195.
